title: Post-transplant hyperlipidaemia: low-dose lovastatin lowers atherogenic lipids without plasma accumulation of lovastatin.
abstract: OBJECTIVE
  The purpose of the present study was twofold. First, to determine the frequency of hyperlipidaemia after heart transplantation (Tx) in relation to values obtained before Tx. Secondly, to examine the effect of low-dose lovastatin on possible antiatherogenic mechanisms and test the hypothesis that the side-effects are dose-dependent.
  
  
  METHODS
  Retrospective study of the frequency of hyperlipidaemia disturbances in heart transplant patients. In addition, in a prospective study, the safety and efficacy of incremental low doses of lovastatin up to 20 mg day-1 were studied, with measurements of its plasma concentration in 24 cyclosporin A treated heart (n = 14) and kidney (n = 10) recipients with total cholesterol > 7.5 mmol L-1.
  
  
  RESULTS
  Cholesterol increased markedly after heart transplantation from a pretransplant value of 5.3 (5.0,5.6) mmol L-1 to 6.7 (6.4,7.0) mmol L-1 after 1 year and then remained constant, but this increase was largely due to a 'normalization' since cholesterol decreased significantly during increasing heart failure before transplantation. Treatment with lovastatin decreased total cholesterol by 19% (P < 0.001), primarily by an effect on LDL cholesterol. HDL cholesterol increased by 15% (P < 0.05), whereas triglycerides remained unchanged. Lovastatin also caused a significant reduction in apolipoprotein B of 16%, and lipid peroxidation of 40%, whereas apolipoprotein A-I, fibrinogen, and glycerol were unchanged. Plasma concentration of lovastatin was significantly higher in transplant recipients compared with controls, but there was no accumulation during incremental dosing of lovastatin. The drug was well tolerated without significant symptoms or evidence of myopathy.
  
  
  CONCLUSIONS
  Hyperlipidaemia is common after cardiac transplantation. Treatment with low dose lovastatin is well tolerated and has a favourable effect on atherogenic lipids.
authors.affiliation: Department of Medicine and Surgery, Rikshopitalet University Hospital, Oslo, Norway.
authors.forename: L
authors.initials: L
authors.lastname: Gullestad
authors.forename: K P
authors.initials: KP
authors.lastname: Nordal
authors.forename: K
authors.initials: K
authors.lastname: Forfang
authors.forename: H
authors.initials: H
authors.lastname: Ihlen
authors.forename: A
authors.initials: A
authors.lastname: Høstmark
authors.forename: K J
authors.initials: KJ
authors.lastname: Berg
authors.forename: H
authors.initials: H
authors.lastname: Cheng
authors.forename: M S
authors.initials: MS
authors.lastname: Schwartz
authors.forename: O
authors.initials: O
authors.lastname: Geiran
authors.forename: S
authors.initials: S
authors.lastname: Simonsen
mesh_terms: D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D005260:Female; D016027:Heart Transplantation; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood* / Q000188:drug therapy*; D015994:Incidence; D008148:Lovastatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D002784:Cholesterol; D008148:Lovastatin